Similar to FGFR1, PARP1 mRNA expression (ILMN_1686871) was approximately 1.81-fold (p < 0.01) higher in dasatinib-resistant pancreatic cancer cells than in dasatinib-sensitive cells (Figure 1A, lower). Here, PARP1 is linked to pancreatic neoplasm.